منابع مشابه
Angiotensin II type 1 receptor blockers.
In the 1970s, a series of observations demonstrated that angiotensin II has deleterious effects on the heart and kidney and that patients with high levels of plasma renin activity are at a higher risk of developing stroke or myocardial infarction than those with low plasma renin activity.1,2 Thereafter, the development of pharmacological probes that block the renin-angiotensin system helped def...
متن کاملMichel Burnier Angiotensin II Type 1 Receptor Blockers
Angiotensin II Type 1 Receptor Blockers Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2001 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/01.CIR.103.6.904 2001;103:904-912 Circulation. http://circ.ahajournals.org/content/103/6/904 World Wide Web at: The online ver...
متن کاملAngiotensin II type 1 receptor blockers and congestive heart failure.
Congestive Heart Failure To the Editor: We read with great interest the review on angiotensin II type 1 receptor blockers by Michel Burnier.1 He quotes previous investigations, including the results of the Losartan Heart Failure Survival Study (ELITE II)2 and states that “. . .losartan was not superior to captopril in reducing morbidity and mortality. . .,” and concludes that “. . .one should b...
متن کاملAngiotensin II receptor blockers.
BUMC PROCEEDINGS 2003;16:123–126 The angiotensin II receptor blockers (ARBs) represent a newer class of antihypertensive agents. Their mechanism of action differs from that of the angiotensin-converting enzyme (ACE) inhibitors, which also affect the renin-angiotensin system. The ARBs were developed to overcome several of the deficiencies of ACE inhibitors: competitive inhibition of ACE results ...
متن کاملAngiotensin II subtype 1 receptor blockers and renal function.
Blood pressure reduction is the most significant factor in delaying onset and progression of renal disease. Blockade of the renin-angiotensin system (RAS) using angiotensin-converting enzyme inhibitors (ACEIs) delays renal disease progression. More recently, agents that block the RAS by preventing angiotensin II from binding to its subtype 1 receptor (ARBs) have been developed in an effort to p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2018
ISSN: 1098-3015
DOI: 10.1016/j.jval.2018.07.265